Increased thirst is not listed amongst the common adverse effects in the Summary of Product Characteristics (SmPC) approved by the MHRA, though some patients do report experiencing thirst during treatment
CJC-1295 dosing approaches: CJC-1295 without DAC (Mod GRF 1-29): Dose: 100-200mcg per injection Frequency: 2-3x daily with meals or before bed Works synergistically with Ipamorelin/GHRP Short half-life, requires frequent dosing CJC-1295 with DAC: Dose: 1-2mg per week total Frequency: 2-3 injections weekly (or single weekly) Long-acting, elevated GH for days More convenient than without DAC Example: 5mg vial + 2ml water = 2,500mcg/ml 1mg dose (1,000mcg) = draw 0.40ml 100mcg dose (without DAC) = draw 0.04ml Most people use CJC-1295 WITH DAC for convenience
We take pride in providing advanced treatments, such as GLP-1 therapy for weight loss and overall wellness, to individuals in the North Dallas community
[DOI] [PubMed] [Google Scholar] Miners JO, Lillywhite KJ, Yoovathaworn K, Pongmarutai M, Birkett DJ
Individual results with any GLP-1 medication vary significantly
These innovations enable controlled release, improved bioavailability, and targeted delivery, thereby optimizing therapeutic outcomes while minimizing adverse effects
